Guyasuta Investment Advisors Inc. Has $3.53 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Guyasuta Investment Advisors Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 8.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 133,217 shares of the biopharmaceutical company’s stock after selling 11,829 shares during the period. Guyasuta Investment Advisors Inc.’s holdings in Pfizer were worth $3,534,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Creative Planning boosted its holdings in shares of Pfizer by 17.1% during the 3rd quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock worth $52,692,000 after buying an additional 266,167 shares during the period. Swedbank AB boosted its holdings in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares during the period. Cornerstone Wealth Management LLC boosted its holdings in Pfizer by 8.1% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 77,912 shares of the biopharmaceutical company’s stock valued at $2,255,000 after purchasing an additional 5,854 shares during the period. nVerses Capital LLC boosted its holdings in Pfizer by 154.1% in the 3rd quarter. nVerses Capital LLC now owns 15,500 shares of the biopharmaceutical company’s stock valued at $449,000 after purchasing an additional 9,400 shares during the period. Finally, Good Life Advisors LLC boosted its holdings in Pfizer by 7.4% in the 3rd quarter. Good Life Advisors LLC now owns 56,199 shares of the biopharmaceutical company’s stock valued at $1,626,000 after purchasing an additional 3,869 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on PFE shares. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Finally, Guggenheim reiterated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Trading Down 0.6 %

NYSE:PFE opened at $25.50 on Friday. The firm’s fifty day moving average is $26.28 and its 200-day moving average is $27.62. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm has a market cap of $144.48 billion, a P/E ratio of 18.08, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The company’s quarterly revenue was up 24.7% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.75%. Pfizer’s dividend payout ratio is currently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.